NCT04155541已完成不适用
Special Investigation for Vizimpro Tablets
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- The number and proportion of patients with ILD (interstitial lung disease)
研究概览
简要总结
Secondary data collection study: safety and efficacy of VIZIMPRO under Japanese medical practice
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 0 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patient with EGFR mutation-positive inoprable or recurrent NSCLC who have not received VIZIMPRO(dacomitinib hydrate)
排除标准
- •Exclusion criteria is not provided in this study
研究组 & 干预措施
VIZIMPRO(dacomitinib hydrate)
Patients with EGFR mutation-positive inoperable or recorrent NSCLN (non-small cell lung cancer) who have not received VIZIMPRO (dacomitinib hydrate)
干预措施: dacomitinib hydrate (Drug)
结局指标
主要结局
The number and proportion of patients with ILD (interstitial lung disease)
时间窗: 52 weeks form the start date
The number and proportion of patients with ILD (interstitial lung disease) will be tabulated by subgroup by risk factor
次要结局
- The number and population of patients with adverse reactions(52 weeks from the start date)
- Response rate(52 weeks from the start date)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Ciprofloxacin Special Drug Use Investigation - To Investigate the Safety and Efficacy in Patients With Ciprofloxacin iv Administration Without DilutionInfectionNCT01690559Bayer704
已完成
不适用
Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid ArthritisRheumatoid Arthritis (RA)NCT03971253Astellas Pharma Inc3,000
终止
不适用
VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Subjects With Underlying Disease at High-risk for Worsening COVID-19Prevention of Infectious Disease Caused by SARS-CoV-2NCT05084755AstraZeneca4
已完成
不适用
All-Case Surveillance of Prizbind®HemorrhageNCT02946931Boehringer Ingelheim1,402
已完成
4 期
Pharmacokinetic Study Of EPZICOM TabletHIV InfectionNCT00337922GlaxoSmithKline8